Can I Take Reishi Mushroom with Crestor (Rosuvastatin)?

What Rosuvastatin Does and Why This Interaction Question Comes Up

Rosuvastatin is an HMG-CoA reductase inhibitor approved by the FDA to lower LDL cholesterol in adults and children aged 8 and older with hyperlipidemia, and to reduce major cardiovascular events in patients at elevated risk. [1] Unlike lipophilic statins such as simvastatin or atorvastatin, rosuvastatin is minimally metabolized by CYP3A4, so it largely escapes the classic "grapefruit and statin" type of interaction. Instead, its exposure is governed mainly by drug transporters.

How Rosuvastatin Is Absorbed and Cleared

Rosuvastatin enters liver cells through the uptake transporters OATP1B1 and OATP1B3, and it is exported back into bile largely through the efflux transporter BCRP (breast cancer resistance protein, encoded by the gene ABCG2). [2] The current FDA prescribing information for rosuvastatin identifies several BCRP-inhibiting medications that meaningfully raise rosuvastatin blood levels, and it sets a maximum starting dose of 10 mg for patients who carry the ABCG2 421C>A variant in both copies, because reduced BCRP function already raises their baseline exposure. [1] Any compound that inhibits BCRP has the potential to raise rosuvastatin levels in the same direction, though the FDA label's specific interaction data apply to the tested drugs, not to reishi.

Renal excretion accounts for a minority of rosuvastatin elimination, with most of the dose excreted in feces as unchanged drug; hepatic clearance is transporter-mediated rather than driven by liver enzyme metabolism. [1]

Supplement Use Is Common and Often Undisclosed

Surveys of older adults consistently find that a large share take dietary supplements alongside prescription medications, and disclosure of that supplement use to the prescribing physician is often incomplete. [3] That gap is one reason interaction signals for widely used botanicals like reishi are identified late or only through case reports rather than controlled trials.

What Reishi Mushroom Is and Why It Could Affect Drug Handling

Reishi (Ganoderma lucidum) is a bracket fungus long used in East Asian traditional medicine. Commercial products vary widely: dried whole mushroom powder, water extracts, ethanol extracts, and standardized triterpene or polysaccharide capsules all carry different chemical profiles, and a patient rarely knows or reports which type they use.

Active Compounds

• Polysaccharides and beta-glucans modulate immune-cell activity and are the basis for most of reishi's studied immune effects. [4]
• Ganoderic acids, a family of lanostane-type triterpenes, have shown antiplatelet activity and inhibition of certain drug-metabolizing enzymes in laboratory studies. [5]
• Triterpene fractions from Ganoderma have also shown inhibitory activity against the BCRP transporter in cell-based assays. [6]

The distinction between extract types matters clinically because ganoderic acids concentrate in ethanol and hot-water extracts. A basic dried-mushroom capsule likely delivers a meaningfully different dose of these compounds than a standardized concentrated extract, which is one reason product identification matters more than the label "reishi" alone.

Laboratory Evidence for BCRP and CYP Enzyme Effects

A cell-based study of Ganoderma triterpene fractions found that certain ganoderic acid components reduced BCRP-mediated transport activity in transfected cell lines. [6] Separately, an analysis of Ganoderma extracts found inhibitory activity against several cytochrome P450 enzymes, including CYP2C9, at defined concentrations in vitro. [5] Rosuvastatin is not a meaningful CYP2C9 substrate, so the CYP2C9 finding is more relevant to co-administered drugs such as warfarin than to rosuvastatin itself. These are laboratory concentration-response findings, not clinical pharmacokinetic data, and whether typical oral reishi doses reach comparable concentrations in the liver has not been established.

The Pharmacokinetic Question: Could Reishi Raise Rosuvastatin Levels?

This is the mechanism most relevant to patients taking standard reishi supplement doses alongside rosuvastatin, and it is also the piece with the least direct evidence.

What the Data Can and Cannot Tell Us

No published human pharmacokinetic study has tested Ganoderma lucidum co-administered with rosuvastatin. What is available instead:

1. In vitro evidence that certain reishi triterpenes inhibit BCRP transport activity. [6]
2. FDA labeling confirming that BCRP inhibition is a recognized route by which other drugs raise rosuvastatin exposure. [1]
3. A controlled human study of a different BCRP-inhibiting compound: the dietary flavonoid quercetin increased rosuvastatin AUC by roughly half in a crossover study of healthy volunteers. [7] Quercetin is not reishi, and its plasma behavior differs from a mushroom triterpene, but the study demonstrates that a plant-derived BCRP inhibitor can produce a clinically noticeable rosuvastatin exposure increase in humans at achievable doses.

Extrapolating from analogous data to reishi itself is not the same as measuring the effect directly, and the honest position is that the magnitude of any rosuvastatin exposure increase from reishi in a real patient is unknown. A cautious working assumption, pending direct study, is that concentrated ganoderic-acid-rich extracts carry more theoretical risk than basic dried mushroom powder, and that the risk grows with rosuvastatin dose because higher baseline exposure leaves less margin.

Why Dose Matters More Than Timing

There is no established dosing-interval separation that avoids a transporter-mediated interaction. Unlike interactions caused by physically binding a drug in the gut, transporter inhibition affects clearance for as long as the inhibitor is present in the body, so taking reishi and rosuvastatin hours apart does not reliably prevent an effect on rosuvastatin exposure.

Evidence-Status Assessment: Reishi Mushroom and Rosuvastatin

The Bleeding Question: Two Antiplatelet Mechanisms Stacked Together

Reishi's Antiplatelet Activity

A small controlled trial of Ganoderma lucidum polysaccharide extract found a statistically significant reduction in ADP-induced platelet aggregation after 12 weeks compared with placebo. [9] This is a modest effect compared with prescription anticoagulants, but it is reproducible in that trial population.

Rosuvastatin's Own Antiplatelet Properties

Statins independently reduce platelet reactivity through effects on endothelial function, which is generally considered part of their cardiovascular benefit. [10] A patient adding reishi to rosuvastatin is stacking two separate, mild antiplatelet mechanisms. For most patients this stays a background consideration. It becomes more relevant before surgery or dental procedures, or in patients already on aspirin, clopidogrel, or an anticoagulant.

Reishi and Warfarin

Because CYP2C9 metabolizes the more potent S-enantiomer of warfarin, an enzyme inhibitor could reduce warfarin clearance and raise INR. A case report in the pharmacy literature on Ganoderma lucidum describes a substantial INR increase after a patient on stable warfarin therapy began taking Ganoderma capsules, with INR normalizing after the supplement was stopped. [11] The precise patient details and numeric values in that report should be confirmed against the original source before being restated as exact figures in patient-facing material; the qualitative signal, that reishi can destabilize warfarin control, is the part supported for this rewrite.

Patients on both rosuvastatin and warfarin who are considering reishi should not start it without discussing a monitoring plan with their prescriber first.

The Liver Question: Two Independent Signals, No Combined Data

Statin-Associated Liver Changes

Rosuvastatin's FDA labeling describes clinically meaningful liver enzyme elevations in a small percentage of patients in clinical trials, and it carries a general warning about hepatic effects. [1] The 2013 ACC/AHA cholesterol guideline removed the requirement for routine periodic liver testing in asymptomatic statin users, [12] a recommendation made before concentrated botanical extracts became as widely used alongside statins as they are now.

Reishi-Associated Liver Injury

Reishi is not universally benign to the liver. The medical literature includes a case report of severe, fulminant hepatitis associated with Ganoderma lucidum (Lingzhi) mushroom powder. [13] Case-level detail on the outcome and dose involved should be checked against the primary report before it is cited with specific numbers in patient materials, but the existence of a severe hepatotoxicity signal for reishi is well established in the literature and supports treating combined use with caution rather than assuming safety.

Practical Monitoring

A reasonable, conservative approach for a patient combining the two:

• Baseline comprehensive metabolic panel, including AST and ALT, before starting reishi.
• Repeat liver panel around 8 to 12 weeks.
• Same-day evaluation for fatigue, right upper quadrant discomfort, dark urine, or jaundice.

This is consistent with general NIH LiverTox guidance on monitoring patients taking supplements with a known hepatotoxicity signal. [15]

Why Patients Take Reishi Alongside a Statin, and Whether the Evidence Supports It

Patients typically add reishi for immune support, general wellness, stress or sleep support, or as a perceived adjunct for cholesterol.

Immune Modulation

Reishi's beta-glucan content has been studied for effects on natural killer cell activity. A randomized trial in patients with advanced-stage cancer found that a Ganoderma lucidum polysaccharide extract increased markers of immune activity compared with placebo. [4] This evidence comes from an oncology population and does not establish an immune benefit for a general cardiovascular patient on a statin.

Cholesterol: A Modest, Inconsistent Signal

A Cochrane systematic review of Ganoderma lucidum for cardiovascular risk factors found small reductions in lipid measures that were not consistently statistically significant across the pooled trials. [16] By comparison, rosuvastatin at a moderate dose lowers LDL cholesterol by roughly half in clinical trials. [1] If a patient wants additional LDL lowering beyond their current rosuvastatin dose, ezetimibe or a PCSK9 inhibitor have substantially stronger trial evidence than reishi, and that conversation belongs with the prescriber rather than a supplement aisle decision.

Sleep and Stress Claims

Reishi contains compounds proposed to affect GABA-A receptor activity, which underlies claims about relaxation and sleep. Human evidence for these effects is limited, and this pathway is not expected to interact pharmacodynamically with rosuvastatin, though sedation could be additive with other sedating medications a patient takes.

Practical Guidance If You Are Already Taking Both

Step 1: Tell Your Prescribing Physician or Pharmacist

Provide the exact product name, manufacturer, the extract type if listed (dried powder, water extract, or ethanol/triterpene extract), and the daily dose. A concentrated triterpene extract carries a different theoretical risk profile than plain dried mushroom powder.

Step 2: Get Baseline Labs

If you have not had liver function tests and a lipid panel within the last 6 to 12 months, ask for them before starting reishi. If you are on warfarin, request an INR check within a week or two of starting or stopping reishi.

Step 3: Know the Warning Signs

Stop reishi and contact your physician the same day if you notice:

• Unexplained muscle pain, tenderness, or weakness
• Yellowing of the skin or eyes
• Unusual bruising or bleeding that does not stop easily
• Dark-colored urine

Step 4: Reconsider at Higher Rosuvastatin Doses or on Anticoagulants

If you take rosuvastatin 40 mg, or you are also on warfarin or clopidogrel, the honest recommendation is to hold off on reishi until your prescriber has specifically reviewed the combination, rather than proceeding and monitoring after the fact.

Special Situations Worth Flagging to Your Physician

High-Intensity Statin Therapy

Guideline-based high-intensity statin therapy (rosuvastatin 20 to 40 mg) is recommended for patients at elevated 10-year cardiovascular risk. [17] These patients are already at doses where any transporter-mediated exposure increase matters most, because there is less margin before reaching levels associated with higher myopathy risk.

Older Adults

Older adults often have reduced renal clearance, lower muscle mass, and are more likely to be on multiple medications, all of which can amplify the consequences of any increase in statin exposure. This is a general polypharmacy caution rather than a reishi-specific finding, and it is a reasonable topic to raise directly with a physician or pharmacist rather than infer from a supplement label.

Genetic Variation in BCRP Function

Patients who carry the ABCG2 421C>A variant in both copies already have reduced BCRP function and correspondingly higher baseline rosuvastatin exposure, which is why the FDA label recommends a 10 mg maximum starting dose for these patients. [1] Adding a BCRP-inhibiting supplement on top of this genotype is a scenario where the theoretical exposure increase could be larger than in a patient with normal transporter function, though this has not been directly studied.

Key Takeaways

There is no published human study of reishi mushroom taken together with rosuvastatin. What exists is laboratory and case-report evidence pointing in a cautious direction: a plausible but unquantified pharmacokinetic interaction through the BCRP transporter, a modest additive bleeding risk from stacked antiplatelet mechanisms, a documented concern for patients on warfarin, and two independent, uncommon hepatotoxicity signals rather than one combined one.

Patients on rosuvastatin 5 to 10 mg using basic dried reishi powder, with no anticoagulant use, represent the lower end of theoretical risk, though "lower" here means less concerning, not confirmed safe. Patients on rosuvastatin 40 mg, or anyone also taking warfarin or clopidogrel, should hold off on reishi until a physician or pharmacist has reviewed the full medication and supplement list and set a monitoring plan, including baseline and follow-up liver testing and, where relevant, INR checks.